SC 13D

Company

Kalaris Therapeutics, Inc.

Filed

August 5, 2022

Accession Number

0001193125-22-213610

A Schedule 13D is filed when an investor acquires more than 5% of a company's shares with an intent to influence control. Learn more about SC 13D filings →